Format

Send to

Choose Destination
Anticancer Res. 2015 Oct;35(10):5607-14.

Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.

Author information

1
Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
2
Department of Radiotherapy, University Medical Centre Utrecht, Utrecht, the Netherlands.
3
Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.
4
Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.
5
Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands f.schramel@antoniusziekenhuis.nl.

Abstract

BACKGROUND:

Surgical resection is the treatment of first choice for patients with stage I-II non-small cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been shown to be a good alternative treatment.

PATIENTS AND METHODS:

Overall survival (OS), progression-free survival (PFS) and recurrence rates were compared between patients with stage I-II NSCLC treated with SBRT (n=53) and those treated with surgical resection (n=175). The propensity score method was used to correct for confounding by indication.

RESULTS:

Before correction, the OS and PFS rates at 1 and 3 years were significantly different between SBRT and surgery, in favor of surgery. After correction, the OS and PFS after SBRT were not significantly different compared to surgery. The recurrence rates for the two treatments were also similar both before and after correction.

CONCLUSION:

This retrospective study showed that clinical outcomes after SBRT are equal to those after surgery in patients with stage I-II NSCLC.

KEYWORDS:

Non-small cell lung cancer; clinical outcome; stage I-II; stereotactic body radiotherapy; surgery

PMID:
26408733
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center